DOCSLIB.ORG

BD Stem Cell Resource Markers of Self-Renewal and Differentiation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BD Stem Cell Resource Markers of Self-Renewal and Differentiation BD Stem Cell Resource Markers of Self-Renewal and Differentiation 23-9953-02 Self Renewing Pathway TGF-β/Activin Sperm Liver Thymus Pancreas Thyroid Lung Intestine Wnt BMP-SMad Erk-MAPK Skin and Hair JAK-STAT Wnt TGF-β/Activin BMP4 bFGF LIF LIFR gp130 Egg p p p Jak β-catenin Smads 175 MEK/ERK Stat3 C-myc Sox2 Oct4 Nanog Smads 2/3 Neural Crest Primordial Germ Cell Stem Cell Neural Stem Cell Self Renewal Ectoderm Embryonic Stem Cell or Induced Pluripotent Endoderm Neurons, Glia Stem Cell Smooth Muscle Cardiac Tissue Chondrocytes Glial Restricted Progenitor Osteocytes Neuronal Type 1 Astrocyte Oligodendrocyte Restricted Progenitor Progenitor Mesoderm Mesenchymal Stem Cell Type 2 Astrocyte Endothelium Oligodendrocyte Neuron Heart Skeletal Muscle Kidney Smooth Muscle Myoblast Adipocyte (Fat) Chondrocyte Fibroblast Osteoblast (Bone) Hemangioblast (Cartilage) Myotube (Muscle) Plasmacytoid Dendritic Cell Hematopoietic Stem Cell Committed Lymphoid Progenitor Monoblast Megakaryoblast Proerythroblast Pre-NK Cell Thymocyte Pre B Cell Myeloblast Erythroblast Progranulocyte Monocyte Myeloid Dendrtitic Cell Megakaryocyte NK Lymphoblast T-Lymphoblast B-Lymphoblast Normoblast Neutrophilic Eosinophilic Basophilic Myelocyte Myelocyte Myelocyte NK Cell T Cell B Cell Macrophage Thrombocytes Reticulocyte Neutrophilic Eosinophilic Basophilic (Platelets) Band Cell Band Cell Band Cell Plasma Cell Erythrocyte Neutrophil Eosinophil Basophil (Red Blood Cell) White colored markers are available from BD Biosciences Ectoderm Markers Embryonic Stem Cells Mesoderm Markers Endoderm Markers Stem Cell Relevant Signaling Astrocytes Neuronal Markers Embryonic Stem Cell Markers Early Mesoderm Markers Heart - Cardiogenesis Markers Hematopoietic Stem Cell Markers Mesenchymal Stem Cell Differentiation Markers Mesenchymal Stem Cell Markers (Fat) Definitive Endoderm Markers Erk-MAPK Signaling TGF Beta Signaling A2B5 GFAP α-Synuclein MAP2B Alkaline Phosphatase Nanog (Human) BMP2 Cryptic α-Actinin CD309 (VEGFR2, KDR) Negative Markers Chondrocyte (Cartilage) Markers Osteoblast (Bone) Markers Negative Markers B-Catenin HNF-1β (TCF-2) basic FGF Mek1 BMPR-II Id3 CD44 Ran-2 α-Synuclein (pY125) MASH1 CD9 Nanog (Mouse) BMP4 MIXL1 Annexin VI CD325 (N-Cadherin) CD184 (CXCR4) HNF-3β (FoxA2) C-Raf Mek1 (pS298) CD119 (IFN-γ receptor α-chain) p16 INK4 FGFR3 S100B β-Tubulin (Tuj1) mGluR1 CD15 (SSEA-1, Lewis X) Nucleostemin Brachyury NF-YA Cardiac specific myosin Connexin-43 CD2 CD24 Aggrecan Matrillin-4 Alkaline Phosphatase IGFBP-3 CD11b (Integrin αM chain) CD79a CD325 (N-Cadherin) Sox17 ERK Mek1/2 (pS222) c-Myc p107 CD24 mGluR1α CD24 Oct3/4 CD31 (PECAM1) Nodal Cardiac Troponin I Desmin CD3 CD33 CD44 Osteonectin Collagen 1 Osteocalcin CD14 CD117 (SCF R, c-kit) GATA4 ERK1 Mek2 DP-1 p300 Early Ectoderm Markers CD56 (NCAM) Nestin CD29 (Integrin β1) Oct3/4A CD34 (Mucosialin, gp 105-120) Sca-1 (Ly6A/E) Cardiac Troponin T Flk-1 (KDR, VEGF-R2, Ly-73) CD4 CD36 CD151 Sox9 Fibronectin RUNX2 CD19 HLA-DR ERK1/2 (pT202/pY204) p38 MAPK (PT180/pY182) E2F-1 PP2A Catalytic α Nestin TP63 CD81 (TAPA-1) NeuroD1 CD30 Podocalyxin CD325 (N-Cadherin) Snail Caveolin-2 GATA4 CD7 CD38 Collagen II CD45 (Leukocyte Common Hepatic Endoderm Markers ERK2 Ras E2F-2 ROCK-I Notch1 CD90 (Thy-1) Neurofilament NF-M CD49f (Integrin α6) Podocalyxin Associated Caveolin-3 GATA6 CD8 CD45 (Leukocyte Common Antigen, Ly-5) ERK3 E2F-3 ROCK-II Myoblast (Muscle) Markers α-Fetoprotein CD90 (Thy-1) CD90.1 (Thy-1.1) Neuron-restricted progenitors CD133 (AC133, Prominin-1) Keratin Sulfate CD13 HAND1 CD10 Antigen, Ly-5) Id1 Smad2/3 Endothelial Cell Markers Positive Markers Albumin CD326 (EpCAM) Neural Crest Cell Markers CD90.2 (Thy-1.2) Neuropilin-2 CD194 (CCR4) PRC2 (Suz12) CD31 (PECAM1) HAND2 CD11b CD45R (B220) Acetylcholinesterase Lactate Dehydrogenase (LDH) Jak-STAT Signaling Id2 SP1 CD14 CD151 ASGPR 1 GATA4 CD112 Nicastrin CD324 (E-Cadherin) Rex-1 CD34 (Mucosialin, gp 105-120) Islet 1 CD13 CD48 Actin Myf-5 CD9 CD73 (Ecto-5’-nucleotidase) CD49d (Integrin α4) MASH1 CD15 (SSEA-1, Lewis X) CD152 (CTLA-4) CD26 HNF-1α CD130 (gp130) STAT4 CD271 (p75, NGFR/NTR) p150 Glued CD326 (EpCAM) Ronin CD66 M-Cadherin CD14 CD56 (NCAM) B-Enolase (ENO-3) MyoD CD10 CD90 (Thy-1) Wnt Signaling CD57 (HNK-1) Neurogenin 3 CD18 (Integrin β2 chain, CR3/CR4) CD157 CD29 (Integrin β1) HNF-1β (TCF-2) STAT1 (C-TERMINUS) STAT4 (pY693) CD325 (N-Cadherin) Pax-5 CD338 (ABCG2) SFRP2 CD66c MLC2a CD15 (SSEA-1, Lewis X) CD97 CD146 (MCAM, MUC18) Pax3 CD13 CD105 (Endoglin) CD271 (p75, NGFR/NTR) Notch1 CD29 (Integrin β1) CD166 (ALCAM) CD44H (Pgp-1, H-CAM) LDLR STAT1 (pY701) STAT5 (MGF) 14-3-3 GSK-3β CD15s (Sialyl Lewis x) CD114 (G-CSF Receptor) CD325 (N-Cadherin) Pax7 CD29 (Integrin β1) CD106 (VCAM-1) ChAT P-glycoprotein c-Myc Smad2/3 CD31 (PECAM1) CD184 (CXCR4) CD106 (VCAM-1) MLC2v STAT3 STAT5 (MGF) (PY694) α-Catenin GSK-3β (pY216) CD16 CD138 (Syndecan-1) Desmin PK-M CD44 CD146 (MCAM, MUC18) CD49f (Integrin α6) Tat-SF1 Neural Stem Cell Markers Contactin PSD-95 Cripto Sox2 CD34 (Mucosialin, gp 105-120) CD192 (CCR2) CD117 (SCF R, c-kit) Myogenin STAT3 (pS727) STAT6 β-Catenin HDAC3 Doublecortin Serotonin Receptor 5-HT 2AR DPPA4 SSEA-3 CD140a (PDGFR ) Myosin Heavy Chain CD19 CD235a CD49d (Integrin α4) CD166 (ALCAM) A2B5 CD349 (Frizzled-9) CD36 CD201 (EPCR) α STAT3 (pY705) STAT6 (pY641) δ-Catenin Jagged1 GABA B Receptor Serotonin Receptor 5-HT 2BR DPPA5 (ESG1) SSEA-4 CD144 (VE-cadherin) NF-YA CD20 GATA3 CD49e (Integrin α5) Fibronectin Intestinal Stem Cell Markers BMI-1 Ki-67 CD45 (Leukocyte Common CD202b (TIE2) Mesenchymal Stem Cell Markers (Bone Marrow) γ-Catenin Lgr5 Gad65 SMN FGF-4 SSEA-5 CD166 (ALCAM) Nkx2.5 CD54 (ICAM-1) HLA I BMI-1 Lgr5 CD15 (SSEA-1, Lewis X) MSI1 (Musashi-1) Antigen, Ly-5) CD202b (TIE2) (pY992) Negative Markers Positive Markers Notch Signaling Akt Neurogenin 3 GAP-43 (Neuromodulin) Synapsin I FoxD3 STAT3 CD172a (SIRPA) P-glycoprotein (MDR) Positive Markers CD55 Vimentin EphB2 Sox9 CD15s (Sialyl Lewis x) MSl2 (Musashi-2) CD45R (B220) CD202b (TIE2) (pY1102) CBP (CREB-Binding Protein) Notch1 CaM Kinase II Nicastrin GluR δ 2 Synaptophysin Frizzled-5 STAT3 (pS727) CD202b (TIE2) SSEA-1 CD11a (Integrin αL chain) CD34 (Mucosialin, gp 105-120) CD10 CD117 (SCF R, c-kit) CD59 CD24 Nanog (Mouse) CD49d (Integrin α4) CD209 BMI-1 CDw93 (C1qRp) Jagged1 Notch2 Casein Kinase I ε Notch1 GluR2 Synaptotagmin GCNF (NR6A1) STAT3 (pY705) CD202b (TIE2) (pY992) Vimentin CD11b (Integrin αM chain) CD45 (Leukocyte Common CD13 CD120a (TNF Receptor Type I) Pancreatic Endoderm Markers CD29 (Integrin β1) Nestin CD49e (Integrin α5) CD209a (CIRE, DC-SIGN) CaM Kinase IV CDw338 (ABCG2) Jagged2 Notch3 Casein Kinase II α PP2A Catalytic α GluR5/6/7 Syntaxin GCTM-2 STAT3-interacting protein 1 CD202b (TIE2) (pY1102) CD14 Antigen, Ly-5) CD14 CD120b (TNF Receptor Type II) Skeletal Muscle Markers CD49f (Integrin 6) Neurogenin 3 CD49f (Integrin α6) Noggin CD49f (Integrin α6) CD213a1 CD31 (PECAM1) DAZL α Neurogenin 3 Notch4 Casein Kinase II β SNAI2 (Slug) Glutamine Synthetase Tau GDF-3 TRA-1-60 Antigen CD19 CD79a CD15 (SSEA-1, Lewis X) CD146 α-Actinin Myf5 CD142 Neuropilin-2 CD54 (ICAM-1) Notch1 CD54 (ICAM-1) CD213a2 CD34 (Mucosialin, gp 105-120) Flk-1 (KDR, VEGF-R2, Ly-73) Nicastrin CBP (CREB-Binding Protein) Wnt16 HNF-3 (FoxA2) TrkB Hsp27 TRA-1-81 Antigen Hemangioblast Markers CD81 (TAPA-1) Pax-6 β CD56 (NCAM) CD249 CD40f (Integrin α6 chain) FOXO1 CD31 (PECAM1) HLA-DR CD29 (Integrin β1) CD166 Actin MyoD Chromogranin A Nkx2.2 Islet-1 Tubby Lefty-A UTF-1 CD95 (Fas/APO-1) Prominin-2 CD62E (E-Selectin) CD252 (OX-40 Ligand) ACE CD324 (E-Cadherin) CD44 G-CSF CD44 (Pgp-1, H-CAM) CD166 (ALCAM) B-Enolase (ENO-3) Myogenin Gad65 Nkx6.1 Jagged1 Tyrosine Hydroxylase Lin-28 Zic3 CD133 (AC133, Prominin-1) PSA-NCAM CD62L (L-Selectin) CD253 (TRAIL) Brachury EphB4 CD59 Gfi-1 CD49d (Integrin α4) CD271 (p75, NGFR/NTR) CD146 (MCAM, MUC18) Myosin heavy chain Glucagon Pancreatic polypeptide MAP2 (a+b) Vimentin CD146 (MCAM, MUC18) Sox1 CD62P (P-Selectin) CD262 (TRAIL-R2, DR5) CD31 (PECAM1) Flk-1 (KDR, VEGF-R2, Ly-73) CD90 (Thy-1) HOXB4 CD49e (Integrin α5) Flk-1 (KDR, VEGF-R2, Ly-73) CD325 (N-Cadherin) Myosin light chain Glut2 Pax-6 Induced Pluripotency Markers CD51 (Integrin αV) GD2 Desmin Titin CD184 (CXCR4) Sox2 Oligodendrocyte Markers CD102 CD322 CD34 (Mucosialin, gp 105-120) GATA1 CD90.1 (Thy-1.1) Jak2 Insulin PDX-1 CD271 (p75, NGFR/NTR) Vimentin c-Myc Nanog CD105 (Endoglin) CD325 (N-Cadherin) CD133 (AC133, Prominin-1) LMO-2 CD105 (Endoglin) Lmo2 CD54 (ICAM-1) Ly-6A/E (Sca-1) M-Cadherin Islet-1 PTF1A CD338 (ABCG2) CD44 O1 KLF4 Oct3/4 CD106 (VCAM-1) CDw93 (C1qRp) CD144 (VE-cadherin) Podocalyxin CD106 (VCAM-1) Ly-6A/E (Sca-1) CD56 (NCAM) Nucleostemin Islet-2 Somatostatin CD44H (Pgp-1, H-CAM) O4 Lin-28 Sox2 CD109 CDw145 CD202b (TIE2) Runx1 (CBFA2) CD117 (SCF R, c-kit) MRP1 CD71 (Transferrin Receptor) SSEA-4 Smooth Muscle Markers NeuroD1 Synaptophysin CD73 (Ecto-5’-nucleotidase) STRO-1 CD140a (PDGFR α) Olig1 CD112 Flk-1 (KDR, VEGF-R2, Ly-73) CD202b (TIE2) (pY992) Tal (SCL) CD133 (AC133, Prominin-1) NF-YA Calmodulin Smooth muscle myosin CD90 (Thy-1) TAZ Primitive Gut Tube Markers Galactocerebroside C Olig2 Primordial Germ Cell Markers CD116 (GM-CSF Receptor) HIF-1α CD202b (TIE2) (pY1102) CD164 Notch1 Desmin Vimentin MBP RIP CD117 (SCF R, c-kit) IP-10 CD184 (CXCR4) P-glycoprotein CD105 (Endoglin) Vimentin CDX2 HNF-1β (TCF-2) Blimp-1 Nanos CD120a (TNF Receptor Type I) Ly-6A/E (Sca-1) CD201 (EPCR) Runx1 (CBFA2) CD106 (VCAM-1) CD15 (SSEA-1, Lewis X) Oct3/4 Skin Precursor Cell Markers CD120b (TNF Receptor Type II) Nestin CD202b (TIE2) Sox7 CD117 (SCF R, c-kit) Piwi/Hiwi CD121a (IL-1 Receptor, Type I/p80) STAT3 CD202b (TIE2) (pY992) Tal (SCL) CRABP2 Sca-1 (Ly6A/E) DAZL Steel CD124 (IL-4 Receptor ) STAT3 (pS727) CD202b (TIE2) (pY1102) WASP (Wiskott-Aldrich Fibronectin Vimentin FABP9 Stella (Dppa3) α CD141 (Thrombomodulin) STAT3 (pY705) CD325 (N-Cadherin) Syndrome Protein) Nestin Fragilis VASA (DDX4) CD144 (VE-cadherin) STAT3-interacting protein 1 Visual System Trophoblast Markers CD146 (MCAM, MUC18) Vimentin CD147 (Neurothelin) CD68 Pax-6 CDX2 Sox7 CD325 (N-Cadherin) Recoverin Cytokeratin 7 Trop-2 For Research Use Only.
Load more

Recommended publications
  • The Prevalence of MADH4 and BMPR1A Mutations in Juvenile Polyposis and Absence of BMPR2, BMPR1B, and ACVR1 Mutations
    484 ORIGINAL ARTICLE J Med Genet: first published as 10.1136/jmg.2004.018598 on 2 July 2004. Downloaded from The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations J R Howe, M G Sayed, A F Ahmed, J Ringold, J Larsen-Haidle, A Merg, F A Mitros, C A Vaccaro, G M Petersen, F M Giardiello, S T Tinley, L A Aaltonen, H T Lynch ............................................................................................................................... J Med Genet 2004;41:484–491. doi: 10.1136/jmg.2004.018598 Background: Juvenile polyposis (JP) is an autosomal dominant syndrome predisposing to colorectal and gastric cancer. We have identified mutations in two genes causing JP, MADH4 and bone morphogenetic protein receptor 1A (BMPR1A): both are involved in bone morphogenetic protein (BMP) mediated signalling and are members of the TGF-b superfamily. This study determined the prevalence of mutations See end of article for in MADH4 and BMPR1A, as well as three other BMP/activin pathway candidate genes in a large number authors’ affiliations ....................... of JP patients. Methods: DNA was extracted from the blood of JP patients and used for PCR amplification of each exon of Correspondence to: these five genes, using primers flanking each intron–exon boundary. Mutations were determined by Dr J R Howe, Department of Surgery, 4644 JCP, comparison to wild type sequences using sequence analysis software. A total of 77 JP cases were University of Iowa College sequenced for mutations in the MADH4, BMPR1A, BMPR1B, BMPR2, and/or ACVR1 (activin A receptor) of Medicine, 200 Hawkins genes. The latter three genes were analysed when MADH4 and BMPR1A sequencing found no mutations.
    [Show full text]
  • Early B-Cell Factors Are Required for Specifying Multiple Retinal Cell Types and Subtypes from Postmitotic Precursors
    11902 • The Journal of Neuroscience, September 8, 2010 • 30(36):11902–11916 Development/Plasticity/Repair Early B-Cell Factors Are Required for Specifying Multiple Retinal Cell Types and Subtypes from Postmitotic Precursors Kangxin Jin,1,2 Haisong Jiang,1,2 Zeqian Mo,3 and Mengqing Xiang1,2 1Center for Advanced Biotechnology and Medicine and Department of Pediatrics, 2Graduate Program in Molecular Genetics, Microbiology and Immunology, and 3Department of Cell Biology and Neuroscience, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854 The establishment of functional retinal circuits in the mammalian retina depends critically on the proper generation and assembly of six classes of neurons, five of which consist of two or more subtypes that differ in morphologies, physiological properties, and/or sublaminar positions. How these diverse neuronal types and subtypes arise during retinogenesis still remains largely to be defined at the molecular level. Here we show that all four family members of the early B-cell factor (Ebf) helix-loop-helix transcription factors are similarly expressedduringmouseretinogenesisinseveralneuronaltypesandsubtypesincludingganglion,amacrine,bipolar,andhorizontalcells, and that their expression in ganglion cells depends on the ganglion cell specification factor Brn3b. Misexpressed Ebfs bias retinal precursors toward the fates of non-AII glycinergic amacrine, type 2 OFF-cone bipolar and horizontal cells, whereas a dominant-negative Ebf suppresses the differentiation of these cells as well as ganglion cells. Reducing Ebf1 expression by RNA interference (RNAi) leads to an inhibitory effect similar to that of the dominant-negative Ebf, effectively neutralizes the promotive effect of wild-type Ebf1, but has no impact on the promotive effect of an RNAi-resistant Ebf1.
    [Show full text]
  • Human Endoglin/CD105 Quantikine
    Quantikine® ELISA Human Endoglin/CD105 Immunoassay Catalog Number DNDG00 For the quantitative determination of human Endoglin concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4 SAMPLE COLLECTION & STORAGE
    [Show full text]
  • Synergetic Effect of Recoverin and Calmodulin on Regulation of Rhodopsin Kinase
    Thomas Jefferson University Jefferson Digital Commons Department of Biochemistry and Molecular Department of Biochemistry and Molecular Biology Faculty Papers Biology 1-1-2012 Synergetic effect of recoverin and calmodulin on regulation of rhodopsin kinase. Ilya I Grigoriev Lomonosov Moscow State University Ivan I Senin Lomonosov Moscow State University Natalya K Tikhomirova Lomonosov Moscow State University Konstantin E Komolov Lomonosov Moscow State University; University of Oldenburg, Oldenburg, Germany; Department of FBiochemistrollow this andy and additional Molecular works Biology at: ,https:/ Thomas/jdc.jeff Jeffersonerson.edu/bmpfp University Ser geiPar tE of P theermy Medicalakov Biochemistry Commons, and the Medical Molecular Biology Commons LetInstitute us for knowBiological Instrumentationhow access of the tRussiano this Academy document of Sciences benefits ouy RecommendedSee next page for Citation additional authors Grigoriev, Ilya I; Senin, Ivan I; Tikhomirova, Natalya K; Komolov, Konstantin E; Permyakov, Sergei E; Zernii, Evgeni Yu; Koch, Karl-Wilhelm; and Philippov, Pavel P, "Synergetic effect of recoverin and calmodulin on regulation of rhodopsin kinase." (2012). Department of Biochemistry and Molecular Biology Faculty Papers. Paper 36. https://jdc.jefferson.edu/bmpfp/36 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Biochemistry and Molecular Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons.
    [Show full text]
  • The Role of the TGF- Co-Receptor Endoglin in Cancer
    1 The role of the TGF- co-receptor endoglin in cancer Eduardo Pérez-Gómez1,†, Gaelle del Castillo1, Juan Francisco Santibáñez2, Jose Miguel López-Novoa3, Carmelo Bernabéu4 and 1,* Miguel Quintanilla . 1Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid, 28029-Madrid, Spain; 2Institute for Medical Research, University of Belgrado, Belgrado, Serbia; 3Instituto Reina Sofía de Investigación Nefrológica, Departamento de Fisiología y Farmacología, Universidad de Salamanca, Salamanca, Spain; 4Centro de Investigaciones Biológicas, CSIC, and CIBER de Enfermedades Raras (CIBERER), Madrid, Spain. E-mails: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected] † Current address: Departamento de Bioquímica y Biología Molecular I, Facultad de Biología, Universidad Complutense de Madrid, Madrid, Spain *Corresponding author 2 ABSTRACT Endoglin (CD105) is an auxiliary membrane receptor of transforming growth factor- (TGF-) that interacts with type I and type II TGF- receptors and modulates TGF- signalling. Mutations in endoglin are involved in Hereditary Hemorrhagic Telangiectasia type I, a disorder characterized by cutaneous telangiectasias, epistaxis (nosebleeds) and major arteriovenous shunts, mainly in liver and lung. Endoglin is overexpressed in the tumor-associated vascular endothelium where it modulates angiogenesis. This feature makes endoglin a promising target for antiangiogenic cancer therapy. Recent studies on human and experimental models of carcinogenesis point to an important tumor cell-autonomous role of endoglin by regulating proliferation, migration, invasion and metastasis. These studies suggest that endoglin behaves as a suppressor of malignancy in experimental and human carcinogenesis. In this review, we evaluate the implication of endoglin in tumor development underlying studies developed in our laboratories in recent years.
    [Show full text]
  • Absence of S100A4 in the Mouse Lens Induces an Aberrant Retina-Specific Differentiation Program and Cataract
    www.nature.com/scientificreports OPEN Absence of S100A4 in the mouse lens induces an aberrant retina‑specifc diferentiation program and cataract Rupalatha Maddala1*, Junyuan Gao2, Richard T. Mathias2, Tylor R. Lewis1, Vadim Y. Arshavsky1,3, Adriana Levine4, Jonathan M. Backer4,5, Anne R. Bresnick4 & Ponugoti V. Rao1,3* S100A4, a member of the S100 family of multifunctional calcium‑binding proteins, participates in several physiological and pathological processes. In this study, we demonstrate that S100A4 expression is robustly induced in diferentiating fber cells of the ocular lens and that S100A4 (−/−) knockout mice develop late‑onset cortical cataracts. Transcriptome profling of lenses from S100A4 (−/−) mice revealed a robust increase in the expression of multiple photoreceptor‑ and Müller glia‑specifc genes, as well as the olfactory sensory neuron‑specifc gene, S100A5. This aberrant transcriptional profle is characterized by corresponding increases in the levels of proteins encoded by the aberrantly upregulated genes. Ingenuity pathway network and curated pathway analyses of diferentially expressed genes in S100A4 (−/−) lenses identifed Crx and Nrl transcription factors as the most signifcant upstream regulators, and revealed that many of the upregulated genes possess promoters containing a high‑density of CpG islands bearing trimethylation marks at histone H3K27 and/or H3K4, respectively. In support of this fnding, we further documented that S100A4 (−/−) knockout lenses have altered levels of trimethylated H3K27 and H3K4. Taken together,
    [Show full text]
  • Molecular Classification of Patients with Unexplained Hamartomatous and Hyperplastic Polyposis
    ORIGINAL CONTRIBUTION Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis Kevin Sweet, MS, CGC Context Significant proportions of patients with hamartomatous polyposis or with Joseph Willis, MD hyperplastic/mixed polyposis remain without specific clinical and molecular diagnosis Xiao-Ping Zhou, MD, PhD or present atypically. Assigning a syndromic diagnosis is important because it guides management, especially surveillance and prophylactic surgery. Carol Gallione, PhD Objective To systematically classify patients with unexplained hamartomatous or hy- Takeshi Sawada, MD, PhD perplastic/mixed polyposis by extensive molecular analysis in the context of central Pia Alhopuro, MD rereview of histopathology results. Sok Kean Khoo, PhD Design, Setting, and Patients Prospective, referral-based study of 49 unrelated patients from outside institutions (n=28) and at a comprehensive cancer center (n=21), Attila Patocs, MD, PhD conducted from May 2, 2002, until December 15, 2004. Germline analysis of PTEN, Cossette Martin, PhD BMPR1A, STK11 (sequence, deletion), SMAD4, and ENG (sequence), specific exon screen- Scott Bridgeman, BSc ing of BRAF, MYH, and BHD, and rereview of polyp histology results were performed. John Heinz, PhD Main Outcome Measures Molecular, clinical, and histopathological findings in pa- tients with unexplained polyposis. Robert Pilarski, MS, CGC Results Of the 49 patients, 11 (22%) had germline mutations. Of 14 patients with Rainer Lehtonen, BSc juvenile polyposis, 2 with early-onset disease had mutations in ENG, encoding endo- Thomas W. Prior, PhD glin, previously only associated with hereditary hemorrhagic telangiectasia; 1 had hemi- zygous deletion encompassing PTEN and BMPR1A; and 1 had an SMAD4 mutation. Thierry Frebourg, MD, PhD One individual previously classified with Peutz-Jeghers syndrome had a PTEN dele- Bin Tean Teh, MD, PhD tion.
    [Show full text]
  • Miami University – the Graduate School
    MIAMI UNIVERSITY – THE GRADUATE SCHOOL CERTIFICATE FOR APPROVING THE DISSERTATION We hereby approve the Dissertation Of Elvis K. Tiburu Candidate for the Degree: Doctor of Philosophy Dr. Gary A. Lorigan, Director Dr. Christopher A. Makaroff, Reader Dr. Robert E. Minto, Reader Dr. Richard T. Taylor, Reader Dr. David G. Pennock Graduate School Representative ABSTRACT DEVELOPMENT OF NEW METHODS FOR THE ALIGNMENT OF LONGER CHAIN PHOSPHOLIPIDS IN BICELLES AND SOLID-STATE NMR STUDIES OF PHOSPHOLAMBAN by Elvis K. Tiburu Magnetically aligned phospholipid bilayers or bicelles are model systems that mimic biological membranes for magnetic resonance studies. A long chain phospholipid bilayer system that spontaneously aligns in a static magnetic field was characterized utilizing solid-state NMR spectroscopy. The oriented membrane system was composed of a mixture of the bilayer-forming phospholipid palmitoylstearoylphosphatidylcholine (PSPC) and the short-chain phospholipid dihexanoylphosphatidylcholine (DHPC) that breaks up the extended bilayers into bilayered micelles or bicelles that are highly hydrated. Traditionally, the shorter 14-carbon chain phospholipid dimyristoyl- phosphatidylcholine (DMPC) has been utilized as the bilayer-forming phospholipid in bicelle studies. The effect of cholesterol in bicelles containing chain perdeuterated 2 DMPC, a partially deuterated (a-[2,2,3,4,4,6- H6]) cholesterol, and stearic acid-d35 has been reported as a function of temperature using 2H solid-state NMR spectroscopy. The order parameters of the labeled probes were calculated and compared with values obtained from unoriented samples in the literature. In addition, 2H solid-state NMR spectroscopy was used to investigate the orientation and side chain dynamics of specific- labeled methyl groups of leucines in PLB in unoriented as well as in magnetically and mechanically aligned phospholipids bilayers.
    [Show full text]
  • Biochemical Journal
    www.biochemj.org Biochem. J. (2007) 405, 199–221 (Printed in Great Britain) doi:10.1042/BJ20070255 199 REVIEW ARTICLE Structures and metal-ion-binding properties of the Ca2+-binding helix–loop–helix EF-hand motifs Jessica L. GIFFORD*, Michael P. WALSH† and Hans J. VOGEL*1 *Structural Biology Research Group, Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada T2N 1N4, and †Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1 The ‘EF-hand’ Ca2+-binding motif plays an essential role in interaction site or structure formation from a molten-globule eukaryotic cellular signalling, and the proteins containing this apo state. EF-hand proteins exhibit various sensitivities to Ca2+, motif constitute a large and functionally diverse family. The EF- reflecting the intrinsic binding ability of the EF-hand as well as hand is defined by its helix–loop–helix secondary structure as the degree of co-operativity in Ca2+ binding to paired EF-hands. well as the ligands presented by the loop to bind the Ca2+ ion. The Two additional factors can influence the ability of an EF-hand identity of these ligands is semi-conserved in the most common to bind Ca2+: selectivity over Mg2+ (a cation with very similar (the ‘canonical’) EF-hand; however, several non-canonical EF- chemical properties to Ca2+ and with a cytoplasmic concentration hands exist that bind Ca2+ by a different co-ordination mechanism. several orders of magnitude higher) and interaction with a protein EF-hands tend to occur in pairs, which form a discrete domain so target.
    [Show full text]
  • Dimerization of Neuronal Calcium Sensor Proteins
    UC Davis UC Davis Previously Published Works Title Dimerization of Neuronal Calcium Sensor Proteins. Permalink https://escholarship.org/uc/item/8426s2jv Author Ames, James B Publication Date 2018 DOI 10.3389/fnmol.2018.00397 Peer reviewed eScholarship.org Powered by the California Digital Library University of California REVIEW published: 02 November 2018 doi: 10.3389/fnmol.2018.00397 Dimerization of Neuronal Calcium Sensor Proteins James B. Ames* Department of Chemistry, University of California, Davis, Davis, CA, United States 2 Neuronal calcium sensor (NCS) proteins are EF-hand containing Ca C binding proteins that regulate sensory signal transduction. Many NCS proteins (recoverin, GCAPs, neurocalcin and visinin-like protein 1 (VILIP1)) form functional dimers under physiological conditions. The dimeric NCS proteins have similar amino acid sequences (50% homology) but each bind to and regulate very different physiological targets. Retinal 2 recoverin binds to rhodopsin kinase and promotes Ca C-dependent desensitization of light-excited rhodopsin during visual phototransduction. The guanylyl cyclase activating proteins (GCAP1–5) each bind and activate retinal guanylyl cyclases (RetGCs) in light- adapted photoreceptors. VILIP1 binds to membrane targets that modulate neuronal secretion. Here, I review atomic-level structures of dimeric forms of recoverin, GCAPs and VILIP1. The distinct dimeric structures in each case suggest that NCS dimerization may play a role in modulating specific target recognition. The dimerization of recoverin 2 2 and VILIP1 is Ca C-dependent and enhances their membrane-targeting Ca C-myristoyl switch function. The dimerization of GCAP1 and GCAP2 facilitate their binding to dimeric 2 RetGCs and may allosterically control the Ca C-dependent activation of RetGCs.
    [Show full text]
  • Differential Expression of Endoglin in Human Melanoma Cells Expressing the V3 Isoform of Versican by Microarray Analysis
    MOLECULAR MEDICINE REPORTS 3: 1035-1039, 2010 Differential expression of endoglin in human melanoma cells expressing the V3 isoform of versican by microarray analysis LAIA MIQUEL-SERRA, DANIEL HERNÁNDEZ, MARÍA-JOSÉ DOCAMPO and ANNA BASSOLS Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain Received May 28, 2010; Accepted August 13, 2010 DOI: 10.3892/mmr.2010.357 Abstract. Versican is a large chondroitin sulfate proteoglycan overexpression reduced tumor growth rate in mice, but favored produced by several tumor types, including malignant mela- the appearance of secondary tumors (12). noma, which exists as four different splice variants. The large Endoglin (ENG, CD105) is a cell surface component of the isoforms V0 and V1 promote melanoma cell proliferation. transforming growth factor (TGF)-β receptor complex (13), We previously described that overexpression of the short V3 which is highly expressed in the tumor-associated vascular isoform in MeWo human melanoma cells markedly reduced endothelium (14) and in tumor cells. The expression of tumor cell growth in vitro and in vivo, but favored the appear- endoglin appears to play an important role in cancer progres- ance of secondary tumors. This study aimed to elucidate the sion, influencing cell proliferation, motility, invasiveness and mechanisms of V3 by identifying differentially expressed tumorigenicity (15). genes between parental and V3-expressing MeWo melanoma In the present study, we used a high-throughput approach cells using microarray analysis. V3 expression significantly to gain further insight into the mechanism by which the V3 reduced the expression of endoglin, a transforming growth isoform exerts its effects on tumor progression.
    [Show full text]
  • Paraneoplastic Neurological and Muscular Syndromes
    Paraneoplastic neurological and muscular syndromes Short compendium Version 4.5, April 2016 By Finn E. Somnier, M.D., D.Sc. (Med.), copyright ® Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark 30/01/2016, Copyright, Finn E. Somnier, MD., D.S. (Med.) Table of contents PARANEOPLASTIC NEUROLOGICAL SYNDROMES .................................................... 4 DEFINITION, SPECIAL FEATURES, IMMUNE MECHANISMS ................................................................ 4 SHORT INTRODUCTION TO THE IMMUNE SYSTEM .................................................. 7 DIAGNOSTIC STRATEGY ..................................................................................................... 12 THERAPEUTIC CONSIDERATIONS .................................................................................. 18 SYNDROMES OF THE CENTRAL NERVOUS SYSTEM ................................................ 22 MORVAN’S FIBRILLARY CHOREA ................................................................................................ 22 PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) ...................................................... 24 Anti-Hu syndrome .................................................................................................................. 25 Anti-Yo syndrome ................................................................................................................... 26 Anti-CV2 / CRMP5 syndrome ............................................................................................
    [Show full text]